EU Data Protection Amendments Could Make Medical Research Impossible, Professors Say

By Zachary Brennan contact

- Last updated on GMT

Professors: EU Data Protection Law Could Make Medical Research Tough
Professors: EU Data Protection Law Could Make Medical Research Tough

Related tags: Research, European union

Epidemiological and other medical research could be prohibitively difficult to conduct if a new European regulation is passed, according to three professors from the University of Amsterdam.

The main goal of the regulation making its way through the European Parliament, known as the General Data Protection Regulation​, is to strengthen the digital privacy rights of Europeans. But the professors claim that a few amendments to the regulation would “make most epidemiological and health research impossible​,” according to an editorial in the British Medical Journal​.

Last December, the European Parliament’s Committee on Civil Liberties, Justice and Home Affairs “called for amendments that would put insurmountable obstacles in the way of research that uses sensitive data, such as health data, especially retrospective studies​,” the professors of health law and social medicine write.

The amendments make few exceptions for processing “personal data concerning health which is necessary for historical, statistical or scientific research purposes​,” such as when that research serves “an ‘exceptionally high public interest,’​” or if “that research cannot possibly be carried out otherwise. The data in question shall be anonymised, or if that is not possible for the research purposes, pseudonymised​.”

But the professors wonder which research will fall under this category of “exceptionally high public interest​” and “who would decide that​.”

The potential of a research project to yield exceptionally important findings is hard to predict because scientific progress is incremental​,” the professors write. “This amendment would prohibit most epidemiological and health research, including research that used data from dead or untraceable patients, retrospective studies, and large scale cohort studies where obtaining informed consent might not be completely impossible but would require disproportionate effort by researchers​.”

Commission oversight

In addition, a committee amendment “proposed to take away the European Commission’s competence to adopt ‘delegated acts’ to further specify criteria and requirements on research using personal data. We think that the commission should remain in the position to make use of its powers and should remove, as urgently as possible, existing obstacles for research across borders​.”

The professors, however, do agree that review by an independent body should be part of the legal framework when non-pseudonymised or directly identifying data are collected and used without explicit consent of the patients involved. “This should also be the case when the research gives rise to specific privacy concerns, such as the collection of genetic data, or when the research has stigmatising consequences for the participants​,” they write.

But the professors call on the committee to use the expertise of ethical review committees, rather than competent supervisory authorities to make the decisions on which research can be accessed “because of their expertise in reviewing research protocols​.”

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us

Products

View more

Webinars